1
|
Mitton-Fry MJ, Arcari JT, Brown MF, Casavant JM, Finegan SM, Flanagan ME, Gao H, George DM, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Irvine R, Lall MS, Megan Lemmon M, Li C, Lin J, McCurdy SP, Mueller JP, Mullins L, Niosi M, Noe MC, Pattavina D, Penzien J, Plummer MS, Risley H, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Winton J, Young JA. Corrigendum to “Novel monobactams utilizing a siderophore uptake mechanism for the treatment of Gram-negative infections” [Bioorg. Med. Chem. Lett. 22/18 (2012) 5989–5994]. Bioorg Med Chem Lett 2015. [DOI: 10.1016/j.bmcl.2015.07.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Brown MF, Mitton-Fry MJ, Arcari JT, Barham R, Casavant J, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Lall MS, Lemmon MM, Li C, Lin J, McCurdy SP, McElroy E, McPherson C, Marr ES, Mueller JP, Mullins L, Nikitenko AA, Noe MC, Penzien J, Plummer MS, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Tomaras A, Young JA, Zaniewski RP. Pyridone-conjugated monobactam antibiotics with gram-negative activity. J Med Chem 2013; 56:5541-52. [PMID: 23755848 DOI: 10.1021/jm400560z] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Herein we describe the structure-aided design and synthesis of a series of pyridone-conjugated monobactam analogues with in vitro antibacterial activity against clinically relevant Gram-negative species including Pseudomonas aeruginosa , Klebsiella pneumoniae , and Escherichia coli . Rat pharmacokinetic studies with compound 17 demonstrate low clearance and low plasma protein binding. In addition, evidence is provided for a number of analogues suggesting that the siderophore receptors PiuA and PirA play a role in drug uptake in P. aeruginosa strain PAO1.
Collapse
Affiliation(s)
- Matthew F Brown
- Worldwide Medicinal Chemistry, ‡Computational Chemistry, §Antibacterials Research Unit, ∥Pharmacokinetics, Dynamics & Metabolism, ⊥Structural Biology, Pfizer Global Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Magee TV, Brown MF, Starr JT, Ackley DC, Abramite JA, Aubrecht J, Butler A, Crandon JL, Dib-Hajj F, Flanagan ME, Granskog K, Hardink JR, Huband MD, Irvine R, Kuhn M, Leach KL, Li B, Lin J, Luke DR, MacVane SH, Miller AA, McCurdy S, McKim JM, Nicolau DP, Nguyen TT, Noe MC, O’Donnell JP, Seibel SB, Shen Y, Stepan AF, Tomaras AP, Wilga PC, Zhang L, Xu J, Chen JM. Discovery of Dap-3 Polymyxin Analogues for the Treatment of Multidrug-Resistant Gram-Negative Nosocomial Infections. J Med Chem 2013; 56:5079-93. [DOI: 10.1021/jm400416u] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Thomas V. Magee
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Matthew F. Brown
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Jeremy T. Starr
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - David C. Ackley
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Joseph A. Abramite
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Jiri Aubrecht
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Andrew Butler
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Jared L. Crandon
- Center
for Anti-Infective Research
and Development, Hartford Hospital, Hartford,
Connecticut 06102, United States
| | - Fadia Dib-Hajj
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Mark E. Flanagan
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Karl Granskog
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Joel R. Hardink
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Michael D. Huband
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Rebecca Irvine
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Michael Kuhn
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Karen L. Leach
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Bryan Li
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Jian Lin
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - David R. Luke
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Shawn H. MacVane
- Center
for Anti-Infective Research
and Development, Hartford Hospital, Hartford,
Connecticut 06102, United States
| | - Alita A. Miller
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Sandra McCurdy
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | | | - David P. Nicolau
- Center
for Anti-Infective Research
and Development, Hartford Hospital, Hartford,
Connecticut 06102, United States
| | - Thuy-Trinh Nguyen
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Mark C. Noe
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - John P. O’Donnell
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Scott B. Seibel
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Yue Shen
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Antonia F. Stepan
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Andrew P. Tomaras
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Paul C. Wilga
- CeeTox, Inc., Kalamazoo, Michigan 49008,
United States
| | - Li Zhang
- WuXi AppTech Co., Ltd., Shanghai, P.R. China
| | | | - Jinshan Michael Chen
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| |
Collapse
|
4
|
Mitton-Fry MJ, Arcari JT, Brown MF, Casavant JM, Finegan SM, Flanagan ME, Gao H, George DM, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Irvine R, Lall MS, Megan Lemmon M, Li C, Lin J, McCurdy SP, Mueller JP, Mullins L, Niosi M, Noe MC, Pattavina D, Penzien J, Plummer MS, Risley H, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Winton J, Young JA. Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections. Bioorg Med Chem Lett 2012; 22:5989-94. [PMID: 22892121 DOI: 10.1016/j.bmcl.2012.07.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2012] [Revised: 06/27/2012] [Accepted: 07/02/2012] [Indexed: 11/16/2022]
Abstract
Novel siderophore-linked monobactams with in vitro and in vivo anti-microbial activity against MDR Gram-negative pathogens are described.
Collapse
Affiliation(s)
- Mark J Mitton-Fry
- Medicinal Chemistry, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Shah M, Huang D, Blick T, Connor A, Reiter LA, Hardink JR, Lynch CC, Waltham M, Thompson EW. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. PLoS One 2012; 7:e29615. [PMID: 22253746 PMCID: PMC3256168 DOI: 10.1371/journal.pone.0029615] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2011] [Accepted: 12/01/2011] [Indexed: 11/19/2022] Open
Abstract
We investigated the effects of the matrix metalloproteinase 13 (MMP13)-selective inhibitor, 5-(4-{4-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]phenoxy}phenoxy)-5-(2-methoxyethyl) pyrimidine-2,4,6(1H,3H,5H)-trione (Cmpd-1), on the primary tumor growth and breast cancer-associated bone remodeling using xenograft and syngeneic mouse models. We used human breast cancer MDA-MB-231 cells inoculated into the mammary fat pad and left ventricle of BALB/c Nu/Nu mice, respectively, and spontaneously metastasizing 4T1.2-Luc mouse mammary cells inoculated into mammary fat pad of BALB/c mice. In a prevention setting, treatment with Cmpd-1 markedly delayed the growth of primary tumors in both models, and reduced the onset and severity of osteolytic lesions in the MDA-MB-231 intracardiac model. Intervention treatment with Cmpd-1 on established MDA-MB-231 primary tumors also significantly inhibited subsequent growth. In contrast, no effects of Cmpd-1 were observed on soft organ metastatic burden following intracardiac or mammary fat pad inoculations of MDA-MB-231 and 4T1.2-Luc cells respectively. MMP13 immunostaining of clinical primary breast tumors and experimental mice tumors revealed intra-tumoral and stromal expression in most tumors, and vasculature expression in all. MMP13 was also detected in osteoblasts in clinical samples of breast-to-bone metastases. The data suggest that MMP13-selective inhibitors, which lack musculoskeletal side effects, may have therapeutic potential both in primary breast cancer and cancer-induced bone osteolysis.
Collapse
Affiliation(s)
- Manisha Shah
- St. Vincent's Institute of Medical Research, St. Vincent's Hospital, Melbourne, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Flanagan ME, Brickner SJ, Lall M, Casavant J, Deschenes L, Finegan SM, George DM, Granskog K, Hardink JR, Huband MD, Hoang T, Lamb L, Marra A, Mitton-Fry M, Mueller JP, Mullins LM, Noe MC, O'Donnell JP, Pattavina D, Penzien JB, Schuff BP, Sun J, Whipple DA, Young J, Gootz TD. Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. ACS Med Chem Lett 2011; 2:385-90. [PMID: 24900319 DOI: 10.1021/ml200012f] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2011] [Accepted: 02/19/2011] [Indexed: 11/28/2022] Open
Abstract
A novel series of monocarbam compounds exhibiting promising antibacterial activity against multidrug resistant Gram-negative microorganisms is reported, along with the synthesis of one such molecule MC-1 (1). Also reported are structure-activity relationships associated with the in vitro and in vivo efficacy of 1 and related analogues in addition to the hydrolytic stability of such compounds and possible implications thereof.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Andrea Marra
- Rib-X Pharmaceuticals, New Haven, Connecticut 06511, United States
| | | | | | | | | | | | | | | | | | | | - David A. Whipple
- Del Shankel Structural Biology Center, University of Kansas, Lawrence, Kansas 66047, United States
| | | | - Thomas D. Gootz
- Thomas Gootz Consulting, LLC, Estes Park, Colorado 80517, United States
| |
Collapse
|
7
|
Magee TV, Ripp SL, Li B, Buzon RA, Chupak L, Dougherty TJ, Finegan SM, Girard D, Hagen AE, Falcone MJ, Farley KA, Granskog K, Hardink JR, Huband MD, Kamicker BJ, Kaneko T, Knickerbocker MJ, Liras JL, Marra A, Medina I, Nguyen TT, Noe MC, Obach RS, O’Donnell JP, Penzien JB, Reilly UD, Schafer JR, Shen Y, Stone GG, Strelevitz TJ, Sun J, Tait-Kamradt A, Vaz ADN, Whipple DA, Widlicka DW, Wishka DG, Wolkowski JP, Flanagan ME. Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections. J Med Chem 2009; 52:7446-57. [DOI: 10.1021/jm900729s] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Thomas V. Magee
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Sharon L. Ripp
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Bryan Li
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Richard A. Buzon
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Lou Chupak
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Thomas J. Dougherty
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Steven M. Finegan
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Dennis Girard
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Anne E. Hagen
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Michael J. Falcone
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Kathleen A. Farley
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Karl Granskog
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Joel R. Hardink
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Michael D. Huband
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Barbara J. Kamicker
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Takushi Kaneko
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | | | - Jennifer L. Liras
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Andrea Marra
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Ivy Medina
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Thuy-Trinh Nguyen
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Mark C. Noe
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - R. Scott Obach
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - John P. O’Donnell
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Joseph B. Penzien
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Usa Datta Reilly
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - John R. Schafer
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Yue Shen
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Gregory G. Stone
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | | | - Jianmin Sun
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Amelia Tait-Kamradt
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Alfin D. N. Vaz
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - David A. Whipple
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Daniel W. Widlicka
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Donn G. Wishka
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Joanna P. Wolkowski
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| | - Mark E. Flanagan
- Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut 06340
| |
Collapse
|
8
|
Reiter LA, Freeman-Cook KD, Jones CS, Martinelli GJ, Antipas AS, Berliner MA, Datta K, Downs JT, Eskra JD, Forman MD, Greer EM, Guzman R, Hardink JR, Janat F, Keene NF, Laird ER, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robertson D, Sperger D, Vaughn-Bowser ML, Waller DM, Yocum SA. Potent, selective pyrimidinetrione-based inhibitors of MMP-13. Bioorg Med Chem Lett 2006; 16:5822-6. [PMID: 16942871 DOI: 10.1016/j.bmcl.2006.08.066] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2006] [Revised: 08/11/2006] [Accepted: 08/14/2006] [Indexed: 11/30/2022]
Abstract
Using SAR from two related series of pyrimidinetrione-based inhibitors, compounds with potent MMP-13 inhibition and >100-fold selectivity against other MMPs have been identified. Despite high molecular weights, clogPs, and polar surface areas, the compounds are generally well absorbed and have excellent pharmacokinetic (PK) properties when dosed as sodium salts. In a rat fibrosis model, a compound from the series displayed no fibrosis at exposures many fold greater than its MMP-13 IC50.
Collapse
Affiliation(s)
- Lawrence A Reiter
- Pfizer Global Research & Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Noe MC, Natarajan V, Snow SL, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Carty TJ, Barberia JA, Sweeney FJ, Liras JL, Vaughn M, Hardink JR, Hawkins JM, Tokar C. Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13. Bioorg Med Chem Lett 2005; 15:2808-11. [PMID: 15911259 DOI: 10.1016/j.bmcl.2005.03.105] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2005] [Revised: 03/07/2005] [Accepted: 03/25/2005] [Indexed: 12/17/2022]
Abstract
A series of pipecolic hydroxamate inhibitors of MMP-13 and aggrecanase was discovered based on screening known inhibitors of TNF-alpha converting enzyme (TACE). Potency versus aggrecanase was optimized by modification of the benzyloxyarylsulfonamide group. Incorporation of geminal alkyl substitution at the 3-position of the piperidine ring improved metabolic stability, presumably by increasing steric hindrance around the metabolically labile hydroxamic acid. This modification also resulted in dramatic improvement of aggrecanase activity with a slight reduction in selectivity versus MMP-1. Synthesis, structure activity relationships, and strategies to reduce metabolic clearance are described.
Collapse
Affiliation(s)
- Mark C Noe
- Pfizer Global Research and Development Groton Laboratories, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Blagg JA, Noe MC, Wolf-Gouveia LA, Reiter LA, Laird ER, Chang SPP, Danley DE, Downs JT, Elliott NC, Eskra JD, Griffiths RJ, Hardink JR, Haugeto AI, Jones CS, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robinson RP, Subramanyam C, Vaughn-Bowser ML, Yocum SA. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett 2005; 15:1807-10. [PMID: 15780611 DOI: 10.1016/j.bmcl.2005.02.038] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2004] [Revised: 02/09/2005] [Accepted: 02/14/2005] [Indexed: 11/20/2022]
Abstract
Through the use of computational modeling, a series of pyrimidinetrione-based inhibitors of MMP-13 was designed based on a lead inhibitor identified through file screening. Incorporation of a biaryl ether moiety at the C-5 position of the pyrimidinetrione ring resulted in a dramatic enhancement of MMP-13 potency. Protein crystallography revealed that this moiety binds in the S(1)(') pocket of the enzyme. Optimization of the C-4 substituent of the terminal aromatic ring led to incorporation of selectivity versus MMP-14 (MT-1 MMP). Structure activity relationships of the biaryl ether substituent are presented as is pharmacokinetic data for a compound that meets our in vitro potency and selectivity goals.
Collapse
Affiliation(s)
- Julian A Blagg
- Pfizer Global Research and Development, Groton Laboratories, MS8220-2471, Eastern Point Road, Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Letavic MA, Barberia JT, Carty TJ, Hardink JR, Liras J, Lopresti-Morrow LL, Mitchell PG, Noe MC, Reeves LM, Snow SL, Stam EJ, Sweeney FJ, Vaughn ML, Yu CH. Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett 2003; 13:3243-6. [PMID: 12951101 DOI: 10.1016/s0960-894x(03)00666-8] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
A series of novel MMP-13 and TNF-alpha converting enzyme inhibitors based on piperazine 2-hydroxamic acid scaffolds are described. The TACE, MMP-1 and MMP-13 activity of these inhibitors as well as the effect of substitution of the piperazine nitrogen and the P-1' benzyloxy tailpiece is discussed. Moderate in vivo activity is observed with several members of this group.
Collapse
Affiliation(s)
- Michael A Letavic
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|